The excessive accumulation of adipose tissue in obesity is associated with multiple inflammatory dermatological diseases. Chemerin, a chemoattractant adipokine, dependent on proteolytical activation, is highly expressed in skin. Different proteases have been reported to activate prochemerin, but none is inherently expressed in human skin. In the present study, we identified a tissue-specific protease and investigated the underlying mechanism of activation at the molecular level. We characterized human KLK7 (kallikrein 7) as a prochemerin processing protease in vitro converting prochemerin into active chemerinF 156 . The activating truncation by the protease might trigger a structural rearrangement leading to an increased affinity of chemerin to CMKLR1 (chemokine-like receptor 1). Molecular modelling and experimental data suggest an underlying ionic interaction in prochemerin C-terminal domains. These findings provide a general molecular basis for the necessity of C-terminal processing of prochemerin. Moreover, immunohistochemistry was used to investigate prochemerin, KLK7 and the recently identified KLK7 inhibitor vaspin expression in human skin biopsies, and distinct co-localization in psoriatic biopsies was observed. On the basis of these results, it is hypothesized that KLK7 activity may contribute to the development of psoriatic lesions as a consequence of excessive chemerin activation and impaired protease activity regulation by vaspin. Therefore this interaction represents an interesting target for psoriasis therapy and treatment of other obesity-related diseases.
INTRODUCTION
Obesity, one of the main epidemics nowadays in the Western world, often correlates with inflammatory skin diseases such as psoriasis [1] [2] [3] . Therefore current investigations are exploring adipokine action in human skin that may lead to this cross-talk. It is known that the expression of pro-inflammatory adipokines such as leptin, TNFα (tumour necrosis factor α), resistin, IL (interleukin)-6 and chemerin is increased in obese humans, whereas the level of the anti-inflammatory adiponectin is lowered. This describes the systemic inflammatory state that is typical for obesity [4] .
Prochemerin was initially discovered in inflamed skin and termed TIG-2 (tazarotene-induced gene 2) [5] . Reports on chemerin action in the context of obesity have established chemoattractant properties as a main functionality of chemerin (reviewed recently in [6] ).
After translation, the 20-amino-acid N-terminal signal sequence of pre-prochemerin is removed during export, liberating prochemerin (Supplementary Figure S1 at http://www.biochemj. org/bj/452/bj4520271add.htm). Circulating prochemerin, starting with Glu 21 and ending with Ser 163 , consists of 143 amino acids and was found to be the target of several serum proteases [7] . Activating proteases include Cat-G (cathepsin G), HLE (human leucocyte elastase) and plasmin, and these proteases cleave prochemerin C-terminally to Phe 156 , Ser 157 or Lys 158 respectively [8, 9] . The truncation of these last five to seven C-terminal amino acids of prochemerin releases active chemerin. This proteolytic processing of prochemerin is required to achieve full activity.
However, the structural necessity of this truncation is not yet understood. Therefore the present study aimed to characterize the molecular and structural mechanisms of prochemerin activation.
Additionally, we were interested in identifying an activating protease inherently expressed in skin. The serine protease KLK7 (kallikrein 7) [10] , also known as SCCE (stratum corneum chymotryptic enzyme), belongs to the family of kallikreinrelated peptidases. As one of the most prominent proteases in skin, this enzyme contributes to desquamation and immune system activation by degrading several different substrates [11] [12] [13] [14] [15] . Human KLK7 prefers aromatic residues at the P1 position within its substrates and we therefore speculated that prochemerin might be a substrate of KLK7. The prochemerin-derived peptide prochem-(138-163) and recombinantly expressed prochemerin were used as possible KLK7 substrates and were found to be truncated after Phe 156 in vitro. To gain further knowledge of the structural consequences of prochemerin truncation, protein structure prediction studies using the ROSETTA program were performed [16] . The model obtained suggested an ionic interaction between Lys 158 , Arg 162 and an acidic cluster in a flanking helix. As a result of the C-terminal truncation, these salt bridges are eliminated, which leads to a complete rearrangement of the C-terminus in the protein model. This was proved experimentally by C-terminal variants and a prochemerin deletion variant, which was as active as chemerin.
Finally, to evaluate potential physiological relevance of KLK7-mediated prochemerin processing, we studied the expression of prochemerin, KLK7 and KLK7-inhibiting serpin vaspin in human skin using IHC (immunohistochemistry). Expression of chemerin and co-localization with KLK7 were increased in psoriatic lesions. Skin-derived prochemerin might therefore be a substrate of KLK7, resulting in processing and rearrangement of the Cterminal aromatic cluster and release of active pro-inflammatory chemerin. Furthermore, KLK7 and vaspin were found distinctly co-localized only in healthy skin, whereas vaspin expression and co-localization with KLK7 clearly decreases in psoriatic skin.
Thus we provide a general molecular mechanism of chemerin activation explaining the necessity of proteolytic processing and propose chemerin, KLK7 and vaspin as promising targets for the treatment of psoriasis.
EXPERIMENTAL Peptide synthesis
Proteolytic processing of prochemerin was initially studied using prochemerin-derived peptides. Peptides prochem-(138-163) (VQRAGEDPHSFYFPGQFAFSKALPRS), chem-(138-157) (VQRAGEDPHSFYFPGQFAFS) and chem-(138-156) (VQRAGEDPHSFYFPGQFAF) were synthesized using an orthogonal Fmoc (fluoren-9-ylmethoxycarbonyl)/tBu (t-butyl) SPPS (solid-phase peptide synthesis) strategy on a Syro II peptide synthesizer (MultiSynTech). Nα-Fmoc-protected amino acids and Wang resins were purchased from Iris Biotechnology, Novabiochem or Bachem. Side-chain protecting groups were tBu (for tyrosine, aspartate, glutamate and serine), trityl (for asparagine, glutamine and histidine), t-butoxycarbonyl (for lysine) and Pbf (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl) (for arginine). Automated peptide synthesis was carried out twice for 40 min using DIC (N,N -di-isopropylcarbodiimide)-and HOBt (1-hydroxybenzotriazole)-activated Fmocprotected amino acids at 10-fold excess. Cleavage of the Fmoc group was achieved using 40 % (v/v) piperidine in DMF (dimethylformamide) for 3 min and 20 % (v/v) piperidine in DMF for 10 min. Peptides were cleaved from the solid support by TFA (trifluoroacetic acid)/thioanisole/thiocresol (90 18 column, 4.6 mm × 250 mm, 90 Å pore size) using two different linear gradient systems of 0.1 % TFA in water and 0.08 % TFA in acetonitrile.
Recombinant proteins: cloning, expression and purification
Peptide-based truncation results were approved using recombinant proteins as substrates. The cDNA of prochemerin was purchased from imaGenes. In a PCR, cDNA fragments encoding prochemerin, chemerinS 157 (chemerin ending at Ser 157 ) or chemerinF 156 (chemerin ending at Phe 156 ) bearing additional restriction sites for NdeI and BamHI were amplified and subsequently ligated into the expression vector pET16b (Merck).
Following the QuikChange ® protocol (Stratagene) point mutations were introduced into the prochemerin sequence using prochemerin-pET16b as template.
Expression of N-terminally His 10 -tagged fusion proteins was carried out in Escherichia coli BL21(DE3)pLysRARE cells after induction by 1 mM IPTG (isopropyl β-D-thiogalactopyranoside). E. coli cells were harvested after 6 h, resuspended in base buffer (25 mM Tris/HCl and 0.5M NaCl, pH 7.8) and lysed using a French press (Thermo Fisher Scientific). Inclusion bodies were washed in urea-containing base buffer (2 M urea, 25 mM Tris/HCl and 0.5M NaCl, pH 7.8), solubilized with 8 M urea base buffer and diluted to 6 M urea base buffer. IMAC (immobilized metal-ionaffinity chromatography) was carried out using Ni-NTA (Ni 2 + -nitrilotriacetate)-agarose-packed columns (Qiagen). Proteincontaining IMAC elution fractions were pooled, diluted to 4 M urea and 0.1 mg of protein/ml, and subjected to a dialysis-based stepwise refolding procedure with decreasing urea concentrations. Purity and identity were confirmed by SDS/PAGE, RP-HPLC (Vydac RP18 column, 4.6 mm × 250 mm, 5 mm particle size, 300 Å pore size), Western blotting and MALDI-TOF-MS. Recombinant vaspin was generated as described previously [17] .
Proteolytic processing of peptides and proteins
Peptides and proteins were tested for KLK7 processing. Thermolysin and KLK7 were obtained from R&D Systems. KLK7 was activated with thermolysin as described previously [17] . Cat-G was purchased from Enzo Life Sciences. Peptide digests were carried out with 1 mM prochem-(138-163) and 50 nM protease for 10 min at 37
• C. After enzymatic digestion, proteolytic activity was terminated by boiling. Subsequently, the peptide mixtures were characterized by analytical RP-HPLC (Phenomenex Jupiter Proteo C 18 column, 4.6 mm × 250 mm, 90 Å pore size). Detected peptide peaks were collected manually and identified by MALDI-TOF-MS.
Kinetic analysis of the proteolytic processing of prochemerinderived peptide prochem-(138-163) was performed as described previously for chemerin-converting enzymes CPB (carboxypeptidase B) and CPN (carboxypeptidase N) [18] . In brief, increasing concentrations of prochem-(138-163) were digested by 50 nM KLK7 or Cat-G and resolved by RP-HPLC as mentioned above. Proteases were diluted from stock solutions with concentrations as given by the manufacturer. The peak areas of resulting peptide products were analysed for quantification.
Recombinant prochemerin and KLK7 were diluted in KLK7 assay buffer to 50 μM and 96 nM respectively and incubated at 25
• C. Samples were taken after 5, 15, 30 and 60 min and subsequently analysed by MALDI-TOF-MS, MS/MS (tandem MS) and SDS/PAGE. Inhibition of KLK7-mediated prochemerin truncation by vaspin was tested using recombinant vaspin. A 4.62 pmol amount of activated KLK7 was incubated with a 10-fold excess of recombinant vaspin in KLK7 assay buffer for 30 min at 25
• C. Subsequently, prochemerin was added to a final concentration of 1 μM, incubated for 90 min at 37
• C and analysed by MALDI-TOF-MS and MS/MS.
Signal transduction assay
C-terminal truncations of prochemerin are known to manipulate the activity at CMKLR1 (chemokine-like receptor 1). Consequently, the influence of KLK7-mediated processing of prochem-(138-163) and recombinant prochemerin was studied. In brief, prochem-(138-163) (100 μM) was digested with KLK7 for 20 min at 25
• C and diluted to 1 μM for the signal transduction assay. Recombinant prochemerin was diluted to 10 μM. Digestion was carried out with KLK7 (19.2 nM) for 30 min at 25
• C. Subsequently, prochemerin in the digest was diluted to 0.1 μM and used for the signal transduction assay. Increased activity of chemerinF 156 was confirmed using recombinant proteins to achieve dose-response curves in the IP (inositol phosphate) accumulation assay as described previously [19] . Briefly, for radioactive labelling, COS-7 cells transiently expressing CMKLR1-eYFP (enhanced yellow fluorescent protein) and chimaeric G-protein Gα 6qi4myr (kindly provided by E. Kostenis, Molecular-, Cellular-and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, Bonn, Germany) were incubated for 16 h in the presence of [ 3 H]myo-inositol. Subsequently, stimulation for 3 h using the appropriated ligand led to intracellular radioactive IP accumulation which was quantified by scintillation counter measurement following cell lysis and anion-exchange chromatography. Experiments were performed in duplicate and repeated at least three times. Results were normalized to 100 % prochemerin-mediated receptor activation and analysed using GraphPad Prism5 software.
Protein structure prediction
To get an insight into prochemerin structure and activation, the ROSETTA program was used to create structural models. The N-terminal domains showed the typical, already predicted, cystatin folding [20] . The comparative modelling functionality of ROSETTA was used to create the N-terminal domain between amino acids 21 and 117 using sialostatin L2 as template [21, 22] . The best model of 10 000 decoys was then used in an ab initio modelling using the topology broker protocol with a fixed Nterminal domain. The resulting 30 000 decoys were clustered with a 2.4 Å radius and a representative model was selected from the best cluster. Additionally, a model for the truncated chemerinF 156 was created following the same protocol.
Cell culture
Prochemerin truncation by KLK7 was studied by the abovementioned methods in vitro. Next, cell culture and IHC studies were performed to confirm this interaction in vivo. After 24 h of dispase digest (2.5 mg/ml; Roche Applied Science), epidermis was trypsinated (0.05 % trypsin/0.02 % EDTA; Biochrom) for 15 min at 37
• C. Cells were filtered through a 70-μm-pore-size mesh and cultured in keratinocyte growth medium (Lonza). Skin fibroblasts were isolated by collagenase digestion (6 units/ml; Sigma) for 30 min and filtration through a 70-μm-pore-size mesh. Subsequently, cells were cultured in DMEM (Dulbecco's modified Eagle's medium) (Biochrom) containing 10 % (v/v) fetal calf serum and 1 % penicillin/streptomycin (Biochrom). Before staining, cells were cultivated on glass coverslips and fixed with 4 % (w/v) paraformaldehyde.
Immunohistochemistry
Prochemerin and KLK7 expression were analysed by IHC studies. The following primary antibodies were used: antichemerin [Abcam, ab112520, diluted 1:50 in PBST (PBS with Tween 20)/0.1 % BSA], anti-KLK7 (Abgent, AP6326a, diluted 1:200 in PBST/0.1 % BSA). Anti-chemerin primary antibody was detected by Alexa Fluor ® 546-conjugated anti-mouse antibody (Invitrogen, A11056, diluted 1:1000 in PBST/0.1 % BSA), whereas Alexa Fluor ® 488-conjugated anti-rabbit antibody (Invitrogen, A11034, diluted 1:500 in PBST/0.1 % BSA) was used to visualize anti-KLK7 primary antibodies. The expression of vaspin in human skin sections was analysed using anti-vaspin primary antibody (Enzo Life Science, ALX-804-730, diluted 1:200 in PBST), which was detected by Alexa Fluor ® 546-conjugated anti-mouse antibody (Invitrogen, A11056, diluted 1:1000 in PBST/0.1 % BSA). Controls were incubated without primary antibodies. Nuclei staining was performed with DAPI (4 ,6-diamidino-2-phenylindole). LS (lesional psoriatic skin) and NLS (non-lesional psoriatic skin) of the same patients (n = 4) as well as skin from healthy individuals (n = 3) were stained at least twice individually and subsequently documented using BZ-9000E analyser software (Keyence). The study was approved by the local ethics committee (005-12-23012012). All subjects gave written informed consent before taking part in the study.
RESULTS
Chemerin is naturally expressed as precursor pre-prochemerin (Supplementary Figure S1 ) requiring proteolytic processing. To study the C-terminal processing of prochemerin by KLK7, different peptides identical with the C-terminus of prochemerin as well as various recombinant proteins were synthesized (Supplementary Table S1 at http://www.biochemj.org/bj/452/bj4520271add.htm).
Preparation of substrates
The peptides were synthesized by automated SPPS, whereas the proteins were generated by recombinant expression in E. coli. All substrates were purified to 95 % homogeneity as shown by analytical RP-HPLC (Supplementary Table S1 and Supplementary Figure S1 ).
Recombinant expression of chemerin variants was carried out in E. coli BL21(DE)pLysRARE cells. IPTG induction led to detectable protein expression after 6 h. Subsequently, all proteins were purified under denaturing conditions and obtained in high purities as confirmed by RP-HPLC and SDS/PAGE with silver staining. Identity of the proteins was confirmed by Western blotting and MALDI-TOF-MS. Correct folding and native disulfide bridge formation resulted in biological activity of the recombinant proteins as tested by the IP accumulation assay using COS-7 cells transiently expressing human CMKLR1 ( Figure 1 ).
Prochemerin-derived peptides are processed by KLK7
Proteolytic processing of the prochemerin-derived peptide prochem-(138-163) ( Figure Figure S2 at http://www.biochemj.org/bj/452/bj4520271add.htm). In parallel, prochem-(138-163) was digested with Cat-G, which is an established prochemerin-activating protease [8] . This serine protease cleaves prochemerin C-terminal to Phe 156 , and thereby exhibits the same cleavage preference as KLK7 for the prochemerin peptide. In addition to the cleavage site identified, prolonged protease digestion led to a truncation after Tyr 149 and Phe 148 (results not shown). On the basis of the identical cleavage site for both enzymes, the proteolytical activity towards prochemerin was analysed using the peptide prochem-(138-163).
Figure 1 Processing of prochemerin improves activity at human CMKLR1
(A) In an initial approach, prochem-(138-163) and recombinant prochemerin were digested with KLK7. Subsequently, these digest approaches were used to stimulate COS-7 cells transiently expressing CMKLR1 with either truncated or undigested ligands as control. IP accumulation was monitored and normalized to undigested ligand. Both proteolytically processed ligands exhibit an approximately 60 % increased activity at human CMKLR1. (B) On account of a potential incomplete turnover of the substrates in (A), recombinant (rec.) proteins were used in the same signal transduction assay. Enhanced activity at human CMKLR1 of chemerinF 156 156 exhibits similar activity at CMKLR1, reflecting potentially the same in vivo behaviour of both molecules. Basal activity was assigned as 0 %, whereas full receptor activation by recombinant prochemerin was set to 100 %. Data were normalized to prochemerin and analysed further using GraphPad Prism5.
KLK7 and Cat-G had activities comparative with that of KLK7, showing slightly higher turnover (Figure 2A ).
Prochemerin proteolysis by KLK7 results in the specifically truncated chemerinF 156 The confirmation of the peptide-based results was achieved by truncation studies performed with recombinant prochemerin and chemerinS 157 . The proteins were incubated with KLK7 and subsequently analysed by SDS/PAGE (Figure 2) 156 were detected. After prolonged incubation, complete conversion into chemerinF 156 was observed, but no further degradation. Additionally, the cleaved peptide SKALPRS was found in the same experiment and sequenced by MS/MS (results not shown). The control experiments using prochemerin without KLK7 or chemerinS 157 with KLK7 showed no degradation of the recombinant fusion proteins. Cleavage after Tyr 149 and Phe 148 could not be detected using recombinant prochemerin. Thus these results confirmed specific Cterminal processing of the proprotein by KLK7, resulting in chemerinF 156 , which was already shown in the prochemerinderived peptide.
As KLK7 is inhibited by the serpin vaspin, we tested the impact of vaspin on the KLK7-mediated prochemerin conversion in vitro [17] . Pre-incubating KLK7 with its inhibitor vaspin completely abolished the processing into chemerinF 156 as monitored by MALDI-TOF-MS (Supplementary Figure S3 at http://www.biochemj.org/bj/452/bj4520271add.htm).
C-terminal truncation by KLK7 enhances chemerin activity at CMKLR1
C-terminal truncations of prochemerin have been reported as a control mechanism of chemerin activity [18] . ChemerinS 157 and chemerinF 156 are the most potent activators of the G-proteincoupled receptor CMKLR1.
The activities of KLK7-processed peptide prochem-(138-163) and of the recombinant prochemerin were analysed using a signal transduction assay as a functional readout system. Human KLK7-processed peptide and protein exhibited enhanced activity compared with untreated controls (Figure 1 ), demonstrating the increased activity of specifically processed chemerinF 156 by KLK7.
These findings were significant in signal transduction assays with recombinant and purified proteins and corresponding peptides ( Figure 1 and Table 1 ). As reported previously, chemerinS 157 (EC 50 21 nM) and chemerinF 156 (EC 50 22 nM) showed significantly higher potencies compared with prochemerin (EC 50 129 nM). Among them, no significant differences were detectable, although chemerinS 157 seemed to be slightly more active. With respect to the synthetic peptides, chem-(138-157) showed an EC 50 value of 35 nM, whereas chem-(138-156) showed a tremendously decreased affinity with an EC 50 value of 811 nM. Even at high concentrations of prochem-(138-163) (10 μM), no full activation of CMKLR1 was achieved and thus no EC 50 value could be determined (EC 50 >1000 nM). Importantly, the last two synthetic peptides displayed significantly lower EC 50 values in comparison with the respective protein ligands.
Prochemerin structure prediction
Protein structure modelling was used to obtain an insight into prochemerin structure and activation. The prochemerin model created consisted of the N-terminal cystatin fold and two Cterminal helices (Figure 3) , suggesting an interaction of Lys 158 , Arg 162 and a glutamate-rich cluster in an adjacent helix. On the basis of this model, it is hypothesized that the truncation of the C-terminal region of prochemerin, leading to the activation, eliminates the interaction between the charged side chains of these amino acids. The structural reasons for the activation were yet unknown, thus a model of chemerinF 156 was created. This model revealed that the small C-terminal helix is truncated and thereby loses the ability to form an ordered structure. Instead, a considerable rearrangement of the C-terminus could be observed ( Figure 3C ).
C-terminal prochemerin mutants substantiate the proposed protein structure model
Different prochemerin variants were generated to approve the structure model hypothesized and the mechanism of activation. Within the prochemerin C-terminus, Lys 158 and Arg 162 were replaced by alanine or glutamate respectively. Moreover, the corresponding double mutants and prochemerin delE, in which the conserved acidic cluster ( Figure 4C ) was mutated to alanine, were cloned, expressed and characterized.
ChemerinS 157 and chemerinF 156 showed increased activity compared with prochemerin. Among the single mutants tested, none showed significantly increased EC 50 values (Figure 4 and Table 1 ). On the basis of the assumption that the deletion of one salt bridge alone might be insufficient to liberate the prochemerin C-terminus completely, the double mutants generated were tested. Both mutants showed a significantly decreased potency ( Table 1) . As prochemerin delE possessing the deletion of the acidic cluster was found to exhibit almost identical activity with that of chemerinF 156 and chemerinS 157 ( Figure 4 and Table 1 ), the accuracy of the proposed model is confirmed. 
Chemerin, KLK7 and vaspin are co-expressed in human skin
Prochemerin and KLK7 expression in human skin-derived cells, cultured primary keratinocytes (Supplementary Figure  S4 at http://www.biochemj.org/bj/452/bj4520271add.htm) and fibroblasts were tested by IHC and found to be positive for both proteins. Furthermore, expression of both proteins was investigated in human skin sections. Prochemerin as well as KLK7 have been separately reported to be expressed in human skin [5, 10] . To study the expression of both proteins within human epidermis and to investigate potential co-localization, requisite for a physiological role of the identified in vitro interaction, we performed IHC studies.
Prochemerin was primarily expressed in the basal layer of healthy skin biopsies. In contrast, expression of KLK7 in healthy skin was predominantly found in the stratum corneum as reflected by the original name of the protease. Thus, in healthy skin, only minor, if any, co-expression of both proteins was observed. Likewise, NLS biopsies of psoriatic patients displayed similar localization of both proteins and featured little or no colocalization.
Strikingly, psoriatic biopsies showed a strong co-expression signal of both proteins in the complete epidermis ( Figure 5C ). These findings demonstrate that KLK7 and substrate prochemerin are expressed in human skin and that particularly chemerin expression is increased in LS where both proteins co-localize in the epidermis. These results provide the first evidence of a physiological role of the KLK7-chemerin interaction and suggest that KLK7-mediated activation of prochemerin is likely to occur in vivo in LS.
We furthermore investigated expression of KLK7 and vaspin, a KLK7-inhibiting serpin, in human epidermis. As reported previously, we found vaspin expression in the epidermal layers in human skin sections [24] (Figure 5B ). In contrast with chemerin, vaspin and target protease KLK7 are clearly co-localized in healthy skin, but expression, as well as co-localization with KLK7, are decreased in LS ( Figure 5B ). 
Figure 4 Mutation of the acidic motif in the prochemerin C-terminus increases receptor activation
Signal transduction assays were performed using different prochemerin mutants. Whereas Lys 158 and Arg 162 mutants failed to induce a significant change in receptor activation compared with prochemerin (A), the deletion of the acidic cluster (prochemerin delE) led to a considerable gain of affinity at CMKLR1 (B). Basal activity was assigned as 0 %, whereas full receptor activation by recombinant prochemerin was set to 100 %. Data were normalized to prochemerin and analysed further using GraphPad Prism5. (C) Protein sequence alignment of chemerin from different species. The alignment revealed the highly conserved acidic cluster. However, within rodents, this cluster is slightly altered. Alignment was carried out with CLUSTALW using the BLOSUM matrix (http://www.genome.jp/tools/clustalw). Sequences were taken from the UniProt database (Sus scrofa, B0LUW3; Bos taurus, Q29RS5; Homo sapiens, Q99969; Pongo abelii: Q5R551; Macaca mulatta, H9H322; Rattus norvegicus, Q5BK77; Cricetulus griseus, Q8HDG8; Mus musculus, Q9DD06)
DISCUSSION
In the present study, KLK7 was identified as a prochemerinprocessing protease, cleaving prochemerin C-terminal to Phe 156 in vitro. On the basis of a predicted prochemerin structure, activation of prochemerin by C-terminal truncation might cause a decomposition of an ionic linkage in the C-terminus. Finally, evidence for an interaction of KLK7 and prochemerin in vivo by IHC studies, which indicates that prochemerin activation by KLK7 might play a relevant role in the context of psoriasis, was found.
As has been shown for other inflammatory conditions such as in a lung disease model, chemerin is suggested to trigger immune cell recruitment by CMKLR1 activation [20, 25] . In particular, pDCs (plasmacytoid dendritic cells), also expressing chemotactic receptors CXCR4 (CXC chemokine receptor 4), CCR7 (CC chemokine receptor 7) and CMKLR1, respond to this chemoattractant protein [26] [27] [28] . However, to induce immune cell migration, the chemerin precursor prochemerin requires proteolytic activation by C-terminal truncation.
Although prochemerin was initially discovered in skin [5] , the main research focus was set on evaluation of chemerin as an adipokine and immune-cell-attracting protein [6] . Thus mainly serine proteases secreted by macrophages and neutrophils including elastase, Cat-G and proteinase-3, have been found to process chemerin. Elastase and Cat-G activate prochemerin preferentially by cleaving after Phe 156 and Ser 157 respectively [8, 9] . Besides these activating proteases, proteinase-3 and chymase have been reported as inactivating proteases [29] .
In 2003, two different active chemerin forms were individually identified as CMKLR1 ligands [20, 25] . Wittamer et al. [20] identified chemerinS 157 originating from ascitic fluid, (A) Expression of KLK7 and chemerin in skin. Human KLK7 was detected using Alexa Fluor ® 488-conjugated anti-KLK7 and anti-rabbit (green) secondary antibodies. For the visualization of chemerin, Alexa Fluor ® 546-conjugated anti-chemerin and anti-mouse (red) secondary antibodies were used. Controls were carried out without primary antibodies; DAPI was used for nuclei staining. Skin biopsies from healthy volunteers (healthy) were compared with biopsies from NLS or LS of the same patients suffering from psoriasis (scale bar, 50 μm). In healthy skin, chemerin is mainly expressed in the basal layer of the epidermis, whereas KLK7 is expressed in the stratum corneum. In NLS, fluorescence intensity of staining for both proteins is slightly up-regulated. In LS, expression of KLK7 and chemerin is clearly increased (as judged by fluorescence intensity of the staining) and co-localizes within the epidermis. (B) KLK7 (green) and inhibitor vaspin are expressed in skin sections of healthy and psoriatic patients.
whereas Meder et al. [25] isolated chemerinF 154 out of human haemofiltrate. Eventually, chemerinA 155 (chemerin ending at Ala 155 ) was isolated from human serum [9] , clearly demonstrating that not one form of active chemerin, but multiple differently processed prochemerin variants are present in humans.
Biological activity was confirmed for all of the different isolated chemerin variants, but chemerinS 157 emerged as the most potent ligand of the CMKLR1 [20, 25, 30] . Wittamer et al. [20, 30] calculated an EC 50 value of 4.5 + − 0.7 nM, whereas the other group [25] only recorded an increase in activity and migration after chemerin stimulation. Thus it was not possible to compare the activity of these different chemerin forms. Finally, Wittamer et al. [30] identified C-terminal truncation of prochemerin as a crucial mechanism for the regulation of activity. Furthermore, they reported decreasing activation of CMKLR1 using different chemerin-derived peptides [30] . In contrast with Meder et al. [25] and Zabel et al. [9] who identified isolated chemerinF 154 and chemerinA 155 as active ligands, Wittamer et al. [30] found the corresponding peptides to be inactive at the CMKLR1. Additionally, Wittamer et al. [30] introduced a chemerinF 156 -related peptide as a ligand with lower potency compared with chemerinS
157 . An explanation for the discrepancy between different ligands might be the usage of a peptide compared with whole proteins. Supporting studies showed that chemerinderived peptides exhibit significantly lower potency at CMKLR1 compared with the full protein ligands [31, 32] . In addition to the core activating sequence, further secondary-structural determinants of the protein ligand that result in optimized receptor activation could explain the shift in potency for protein and related peptidic ligands. However, the molecular background underlying the necessity of C-terminal truncations of prochemerin is still not understood.
In the present study, chemerinF 156 , generated by KLK7, was characterized as an active ligand of CMKLR1. Although we found cleavage sites after Tyr 149 and Phe 148 using a prochemerin-related peptide, these sites could not be confirmed for the processing of the recombinant prochemerin, and thus resemble artefacts for the synthetic prochemerin peptide only. On the basis of the prochemerin model obtained, it was assumed that these positions are shielded against KLK7 cleavage by the overall protein structure.
As shown by Findeisen et al. [19] , evaluating EC 50 values of NPFF (neuropeptide FF) receptor ligands, comparison of different EC 50 values resulting from different signal transduction assays is not always suitable. Therefore recombinant chemerinS 157 was used as a reference in the signal transduction assay and featured potency comparable with that of chemerinF 156 . These results suggest the same activity of both proteins in vivo and indicate physiological functions for multiple proteases in the conversion of the proprotein into activated chemerin variants.
The serine protease KLK7, initially identified as SCCE, is mainly expressed in stratum corneum [10] , which could be confirmed by IHC in the present study. KLK7 belongs to a 15-membered serine protease family, most closely related to KLK4 (kallikrein 4) and KLK5 (kallikrein 5) [33] . High expression of KLK7 is also found in CNS (central nervous system), kidney and breast tissue [33] . Evidence for increased expression of KLK7 in endocrine-related malignancies such as ovarian cancer has been found [34, 35] .
Screening a peptide library for substrate specificity of multiple kallikreins, Debela et al. [36] identified aromatic residues such as phenylalanine and especially tyrosine as preferred amino acids at the P1 position for KLK7. As substrates of KLK7, several membrane-associated proteins were reported. Different cell-cell adhesion molecules such as CDSN (corneodesmosin), DSC1 (desmocollin 1) and DSG2 (desmoglein 2) are cleaved by KLK7 [11, 14] . By degrading these molecules, KLK7 is proposed to contribute to desquamation in skin or invasive processes in prostate cancer. Moreover, LL-37 originating from cathelicidin was found to be a substrate of KLK7 [15] . Interestingly, prochemerin is proposed to adopt a similar folding to that of cathelicidin [20] . In addition, KLK7 modulates immune cell migration by processing chemoattractant proteins such as IL-1β in human epidermis [13] . Since chemoattractant activity also has been reported for chemerin [20, 37] , these are strong indications that activation of immune cells represents a principal function of KLK7 in skin.
Next, protein structure prediction studies were performed to explore prochemerin activation and revealed a first insight into a hypothetical activation mechanism. Both prochemerin and chemerinF 156 models contained the already predicted Nterminal cystatin-like structure [20] , and a long C-terminal helix. Furthermore, prochemerin exhibited an additional C-terminal helix.
Zabel et al. [38] referred to the chemerin structure as reverse chemokine folding. In contrast with chemerin, chemokines exhibit a central helix flanked by a flexible N-terminus and fixed C-terminus. As with chemerin, some chemokines require proteolytic truncation of their N-terminus to gain full potency [39] . Consequently, the removal of the very first amino acids might represent a similar activation mechanism as for prochemerin. Within chemerin, full activity is obtained after truncation of Arg 162 and Lys 158 [20] . Allen et al. [40] carried out NMR assignment of recombinant chemerinA 155 that showed a rather unstructured protein with only four distinct secondary-structure elements. Aside from this assignment, to our knowledge, no further structural information has been reported. Interestingly, Allen et al. [40] found a C-terminal helix that contains the final cysteine residue. In good agreement with these earlier findings, the second last helix of our prochemerin model contained this cysteine residue as well. In contrast with Allen et al. [40] , our prochemerin model predicted an additional helix, which ranged from Phe 154 to Ala 159 and included most of the cleavage positions identified so far. This helix seems to be disturbed after cleavage, as found in the chemerinF 156 model (Figure 3 ). The discrepancy between the chemerin structures might be due to the different chemerin forms used for prediction and NMR assignment. However, it might also be a strong indication that the proposed C-terminal rearrangement, seen in the chemerinF 156 model, occurs subsequently to the truncation of prochemerin.
Within the prochemerin model obtained, an ionic interaction between Arg 162 , Lys 158 and the acidic cluster within the adjacent helix was proposed by protein structure prediction. This acidic cluster is conserved within most mammalian species. Rodents alone feature deletions in this region. On the basis of the high flexibility in the prochemerin model, an altered connection pattern of the residues identified might occur in these animals. Consequently, the interaction identified is most likely to be present within rodents as well. Within human prochemerin, both basic amino acids within the C-terminus prevent the full activation, because chemerinK 158 exhibited an increased, but not full, potency as found for chemerinS 157 [7] . Accordingly, the individual exchanges of Arg 162 and Lys 158 in the recombinant proteins featured potency similar to that of prochemerin. On the basis of this assumption, one would expect an increased activity of the doubly mutated prochemerin variants K158A/R162A and K158E/R162E. Surprisingly, these variants showed decreased potency. Thus the prochemerin delE variant, which lacks the acidic cluster, was generated and tested. Using this mutant, full activity was recovered, which supports the predicted prochemerin structure and the proposed activation mechanism. The negative charges of glutamate residues at position 158 and 162 might lead to repulsion from the CMKLR1, whereas the C-terminus almost exclusively features uncharged residues in the alanine double mutant. This might result in rearrangement triggered by hydrophobic interaction, providing an explanation for the decreased affinity of the double mutant. In contrast, the positive charge of arginine and lysine in the prolonged terminus of prochemerin delE seems to be tolerated by the receptor.
The function of chemerin in skin is still a matter of debate. Particularly, chemerin expression and regulation in cutaneous layers is discussed controversially [5, 32, 41, 42] . In the present study, co-expression of prochemerin and KLK7 in LS biopsies was demonstrated. Chemerin is one of the most important chemoattractant of pDCs, the initial effector cells in psoriasis [26, 28, 37, 41] . These cells were reported to affect psoriasis by releasing IFNα (interferon α) [43] . The activation of prochemerin by KLK7 might therefore contribute to pDC recruitment to diseased skin and represent a molecular mechanism for the implication of KLK7 and chemerin in the initiation and progress of psoriasis. In the Human Protein Atlas database (http://www.proteinatlas.org), elastase and Cat-G expression in skin are all negative in keratinocytes, fibroblasts and melanocytes according to IHC-based expression data [44] . Importantly, with increasing neutrophil and macrophage invasion in the inflamed skin, the pro-inflammatory chemerin-activating proteases plasmin, Cat-G and elastase are likely to contribute to the impact of chemerin on inflammatory processes [45, 46] .
In the present study, we have demonstrated KLK7 expression in fibroblasts. In this context, KLK7-mediated prochemerin activation in psoriatic skin might also explain results previously reported by Albanesi et al. [41] , who showed increased pDC migration towards fibroblast supernatant originating from psoriatic biopsies. Although expression of chemerin was increased only 2-fold (321 + − 31 pg/ml compared with 702 + − 110 pg/ml), diluted LS supernatant (1:81) induced pDC recruitment dramatically. In comparison, supernatant of healthy as well as that of NLS even at lower dilutions (1:9) did not attract pDCs. Involvement of the chemerin/CMKLR1 axis was confirmed by usage of an anti-CMKLR1 antibody, terminating migration and recombinant chemerin leading to increased pDC recruitment. The significant increase in activity for LS-derived fibroblast supernatants cannot be explained by the increased chemerin protein expression alone and suggests a shift to the active chemerin form in psoriatic skin. But as Albanesi et al. [41] did not use anti-chemerin antibodies able to distinguish between unprocessed prochemerin and active chemerin variants, this can only be speculated.
On the basis of previous results demonstrating KLK7 involvement in desquamation and deregulated hyperproliferation in skin [11, 47] , and our results reporting the processing of prochemerin, the regulation of KLK7 activity is likely to be a crucial process in normal skin homoeostasis.
On the basis of IHC data of the present study, KLK7 expression does not seem to be obviously increased from normal to LS. But, whereas up-regulation of expression is one possible mechanism that could lead to increased KLK7 activity in LS, deficiency in protease regulation/inhibition might as well contribute to increased chemerin activation. We have recently identified vaspin, serpinA12, as an inhibitor of KLK7 [17] . Vaspin is also expressed in human skin keratinocytes and expression is significantly downregulated in psoriatic skin [24] . In the present study, IHC data demonstrate that both vaspin expression and co-localization with KLK7 is decreased in LS. These results suggest that deregulated control of KLK7 activity might contribute to increased KLK7 activity and chemerin processing in psoriatic skin, whereas expression of the protease might not drastically change.
In line with this, misguided regulation of KLK7 action, as a consequence of a mutation within the SPINK5 (serine peptidase inhibitor, Kazal type 5) gene, results in Netherton syndrome, an autosomal recessive skin disease associated with massive skin desquamation [48, 49] . Even more striking, Klk7-transgenic mice exhibit a phenotype comparable with psoriasis, including cutaneous hyperproliferation and immune cell infiltration [50] . This clearly demonstrates the precedence of appropriate regulation of this protease in skin.
Inhibition of human kallikrein-related peptidases by endogenous and synthetic regulators has been reviewed elsewhere [51, 52] . Different KLK7 inhibitors, e.g. from the serpin family (α 1 -antitrypsin, kallistatin), and LEKTI-1 (lymphoepithelial Kazal-type 5 serine protease inhibitor 1) of the Kazal type of inhibitors have been reported in vitro [51, 52] . In addition, smallmolecule inhibitors of promising specificity for KLK7 were investigated. Teixeira et al. [53] In summary, we provide a general molecular mechanism of chemerin activation explaining the necessity of proteolytical processing and suggest chemerin, KLK7 and vaspin as promising targets for the treatment of psoriasis. Furthermore, the activation of prochemerin by KLK7 might not be restricted to skin. Taking into account the expression of chemerin and KLK7 demonstrated in pancreas [12, 54, 55] and the reported role of chemerin in β-cell function, it can be speculated that KLK7-mediated prochemerin activation might represent a general mechanism in vivo.
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